Form 4: Director Ian T. Clark Receives Corvus Pharmaceuticals Grant

Corvus Pharmaceuticals director Ian T. Clark was granted 15,000 stock options as part of his compensation package.

Summary

• Director Ian T. Clark was granted 15,000 stock options to purchase common stock in Corvus Pharmaceuticals.
• The options have an exercise price of $11.60 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Corvus Pharmaceuticals common stock.

Future Outlook

The options vest 100% on the earlier of the first anniversary of the grant date or the date of the 2027 Annual Meeting of stockholders, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure alignment with long-term strategic goals.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for small-cap biotech firms.
• The 10-year expiration term is a standard duration for executive and director stock option plans.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 11, 2027, or the 2027 Annual Meeting.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Form 4, Insider Trading, Stock Options, Director Compensation